The regenerative medicine company said the funds would help upgrade utilities and infrastructure at the site, while the technical staff needed to operate a second shift at its original facility in the city had been recruited and were in the process of being trained.
Monthly processing throughput has already more than doubled in the year to the third quarter, TRX said, with additional products expected to become available towards the end of the fourth quarter.
The company added that it was currently working with its existing outsourcing provider to increase the yield of DermaPure, its soft tissue repair product.
"We have excellent products for which demand is exceeding our current capacity. Therefore, our current focus is ensuring we can increase our capacity to meet this significant demand", said TRX’s executive chairman John Samuel.
The group also released a trading update for its current full year, saying that an increase in throughput was now expected for the fourth quarter, as opposed to earlier in the second half, and as a result its revenues for 2019 were now expected to be 15-20% below current market consensus, which would, in turn, reduce its margins and impact earnings (EBITDA).
However, the firm reiterated that demand for its products “remains strong” and that it did not expect any longer-term impact beyond a current three-month delay to an increase of its manufacturing capacity.
In early trading on Thursday, Tissue Regenix shares were 9.5% lower at 2.9p.